Epratuzumab

A4DAB107 | Cancer | Phase-III
SIGLEC2/CD22
G1 / IgG1
Charite - Universitatsmedizin Berlin Children's Oncology Group Immunomedics National Cancer Institute (USA) UCB
Phase-III
Whole mAb
AMG 412 AMG412 AGM-412 Epratucyn IMMU 103 IMMU103 IMMU-103 IMMU LL2 IMMU-LL2 LymphoCide
—
IMGT PubChem (135308971) PubChem (160682287) PubChem (249565768) PubChem (347909859) PubChem (472220415) PubChem (472420636) PubChem (474488726) PubChem (474489072) PubChem (505586723) PubChem (519819851) Thera-SAbDab YAbS
Avg A4D Score
-0.725
Score Range
-0.74 to -0.72
Structures
6
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB107_5vl3_C_D 5vl3 99% -0.7448 6.5 4.0 -0.3659 -0.7927
A4DAB107_5vl3_E_F 5vl3 99% -0.7255 6.5 9.0 -0.3122 -0.7789
A4DAB107_5vl3_A_B 5vl3 99% -0.7198 6.5 9.0 -0.3289 -0.7693
A4DAB107_5vl3_H_L 5vl3 99% -0.7263 6.5 9.0 -0.3222 -0.7775
A4DAB107_5vkk_H_L 5vkk 99% -0.7174 6.5 4.0 -0.3403 -0.764
A4DAB107_5vkk_A_B 5vkk 99% -0.7161 6.5 4.0 N/A N/A